Cryolife Inc (NYSE:CRY) Director C Elkins Ronald sold 1,000 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $20.00, for a total value of $20,000.00. Following the completion of the transaction, the director now owns 99,849 shares in the company, valued at approximately $1,996,980. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

C Elkins Ronald also recently made the following trade(s):

  • On Monday, November 6th, C Elkins Ronald sold 1,000 shares of Cryolife stock. The stock was sold at an average price of $19.03, for a total value of $19,030.00.

Cryolife Inc (NYSE:CRY) traded down $0.05 during trading hours on Wednesday, hitting $19.95. The company had a trading volume of 129,900 shares, compared to its average volume of 160,010. The company has a debt-to-equity ratio of 0.29, a quick ratio of 4.90 and a current ratio of 5.96. Cryolife Inc has a fifty-two week low of $14.02 and a fifty-two week high of $24.00. The firm has a market capitalization of $721.00, a PE ratio of 48.78 and a beta of 0.82.

Cryolife (NYSE:CRY) last announced its quarterly earnings data on Monday, October 30th. The medical equipment provider reported $0.08 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.08. The firm had revenue of $44.00 million during the quarter, compared to analyst estimates of $44.60 million. Cryolife had a return on equity of 6.43% and a net margin of 5.28%. Cryolife’s quarterly revenue was down 2.9% on a year-over-year basis. During the same period in the previous year, the company earned $0.13 earnings per share. equities research analysts expect that Cryolife Inc will post 0.28 EPS for the current fiscal year.

CRY has been the topic of several recent analyst reports. Lake Street Capital boosted their price target on Cryolife to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, October 11th. TheStreet cut Cryolife from a “b” rating to a “c+” rating in a research note on Monday, October 30th. Zacks Investment Research cut Cryolife from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Northland Securities reiterated a “buy” rating and issued a $23.50 price target on shares of Cryolife in a research note on Monday, November 13th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $25.00 price target on shares of Cryolife in a research note on Monday, October 9th. Two analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. Cryolife currently has an average rating of “Hold” and a consensus target price of $23.63.

A number of institutional investors have recently made changes to their positions in CRY. Russell Investments Group Ltd. bought a new stake in Cryolife in the third quarter valued at about $6,164,000. William Blair Investment Management LLC bought a new stake in Cryolife in the second quarter valued at about $4,517,000. Macquarie Group Ltd. increased its holdings in Cryolife by 16.0% in the third quarter. Macquarie Group Ltd. now owns 1,609,284 shares of the medical equipment provider’s stock valued at $36,531,000 after buying an additional 221,574 shares during the last quarter. Thomson Horstmann & Bryant Inc. increased its holdings in Cryolife by 139.0% in the third quarter. Thomson Horstmann & Bryant Inc. now owns 224,518 shares of the medical equipment provider’s stock valued at $5,096,000 after buying an additional 130,593 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in Cryolife by 6.0% in the second quarter. Dimensional Fund Advisors LP now owns 1,960,221 shares of the medical equipment provider’s stock valued at $39,107,000 after buying an additional 110,973 shares during the last quarter. 73.28% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This report was first posted by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.dailypolitical.com/2017/12/20/cryolife-inc-cry-director-c-elkins-ronald-sells-1000-shares.html.

Cryolife Company Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Insider Buying and Selling by Quarter for Cryolife (NYSE:CRY)

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.